These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36111020)

  • 1. The prognostic benefit from intermediate-dose cytarabine as consolidation therapy varies by cytogenetic subtype in t(8;21) acute myeloid leukemia: a retrospective cohort study.
    Chen G; Yang J; Cao F; Zhou W; Gong D; Liu L; Zhou D
    Ann Transl Med; 2022 Aug; 10(16):858. PubMed ID: 36111020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients.
    Tangchitpianvit K; Rattarittamrong E; Chai-Adisaksopha C; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Tantiworawit A; Norasetthada L
    Hematology; 2021 Dec; 26(1):355-364. PubMed ID: 33853503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Three Doses of Cytarabine Consolidation for Intermediate- and Adverse-risk Acute Myeloid Leukemia: Real World Evidence From Thai Acute Myeloid Leukemia Registry.
    Chanswangphuwana C; Polprasert C; Owattanapanich W; Kungwankiattichai S; Rattarittamrong E; Rattanathammethee T; Limvorapitak W; Saengboon S; Niparuck P; Puavilai T; Julamanee J; Saelue P; Wanitpongpun C; Nakhakes C; Prayongratana K; Sriswasdi C
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e915-e921. PubMed ID: 35792033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry.
    Hanoun M; Ruhnke L; Kramer M; Hanoun C; Schäfer-Eckart K; Steffen B; Sauer T; Krause SW; Schliemann C; Mikesch JH; Kaufmann M; Hänel M; Jost E; Brümmendorf TH; Fransecky L; Kraus S; Einsele H; Niemann D; Neubauer A; Kullmer J; Seggewiss-Bernhard R; Görner M; Held G; Kaiser U; Scholl S; Hochhaus A; Reinhardt HC; Platzbecker U; Baldus CD; Müller-Tidow C; Bornhäuser M; Serve H; Röllig C;
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4611-4621. PubMed ID: 36167894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia.
    Niparuck P; Limsuwanachot N; Pukiat S; Chantrathammachart P; Rerkamnuaychoke B; Magmuang S; Phusanti S; Boonyawat K; Puavilai T; Angchaisuksiri P; Ungkanont A; Chuncharunee S
    Exp Hematol Oncol; 2019; 8():3. PubMed ID: 30729065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
    Visani G; Bernasconi P; Boni M; Castoldi GL; Ciolli S; Clavio M; Cox MC; Cuneo A; Del Poeta G; Dini D; Falzetti D; Fanin R; Gobbi M; Isidori A; Leoni F; Liso V; Malagola M; Martinelli G; Mecucci C; Piccaluga PP; Petti MC; Rondelli R; Russo D; Sessarego M; Specchia G; Testoni N; Torelli G; Mandelli F; Tura S
    Leukemia; 2001 Jun; 15(6):903-9. PubMed ID: 11417475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of HIDAC 18 g Versus IDAC 9 g in Consolidation Therapy of Acute Myeloid Leukemia: A Retrospective Study.
    Ravikumar D; Saju H; Choudary A; Bhattacharjee A; Dubashi B; Ganesan P; Kayal S
    Indian J Hematol Blood Transfus; 2022 Jan; 38(1):31-41. PubMed ID: 35125710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?
    Derman BA; Larson RA
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101102. PubMed ID: 31779969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
    Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
    Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Clinical Efficacy of Cytarabine with Different Regimens in Postremission Consolidation Therapy for Adult t(8;21) AML Patients: A Multicenter Retrospective Study in China.
    Gong D; Li W; Hu LD; Shen JL; Fang MY; Yang QM; Wang HX; Ke XY; Chen HR; Wang Z; Liu H; Liu F; Ma YG; Wang JW; Li HH; Wang QS; Jing Y; Gao XN; Dou LP; Li YH; Luo JM; Yu L
    Acta Haematol; 2016; 136(4):201-209. PubMed ID: 27640088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study.
    Mantovani L; Hasenclever D; Krahl R; Pönisch W; Herold M; Pasold R; Fiedler F; Dölken G; Kämpfe D; Schmoll HJ; Súbert R; Kubel M; Niederwieser D; Helbig W;
    Leuk Lymphoma; 2002 Feb; 43(2):265-74. PubMed ID: 11999557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of assessing cytogenetic and molecular risk factors in acute myeloid leukemia therapy.
    Coles EC; Colita A; Momanu R; Berbec N; Ivanescu AM; Oprea M; Jardan D; Jardan C; Arghir A; Coriu D; Lupu AR
    J Med Life; 2012; 5(Spec Issue):36-43. PubMed ID: 31803284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A retrospective analysis of prognosis in favorable-risk acute myeloid leukemia patients with different consolidation regimens].
    Wang HY; Bao XB; Tang XW; Sun AN; Wu DP; Zhou HX; Qiu HY
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):517-522. PubMed ID: 28655096
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics.
    Zhou JH; Lin HQ; Shen Q; Hu LN; Li GQ; Sun XF; Zhang XY
    Curr Med Sci; 2018 Feb; 38(1):51-57. PubMed ID: 30074151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
    Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T
    Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.
    Klein K; Kaspers G; Harrison CJ; Beverloo HB; Reedijk A; Bongers M; Cloos J; Pession A; Reinhardt D; Zimmerman M; Creutzig U; Dworzak M; Alonzo T; Johnston D; Hirsch B; Zapotocky M; De Moerloose B; Fynn A; Lee V; Taga T; Tawa A; Auvrignon A; Zeller B; Forestier E; Salgado C; Balwierz W; Popa A; Rubnitz J; Raimondi S; Gibson B
    J Clin Oncol; 2015 Dec; 33(36):4247-58. PubMed ID: 26573082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
    Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
    Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
    Li R; Hu X; Wang L; Cheng H; Lv S; Zhang W; Wang J; Yang J; Song X
    Am J Hematol; 2017 Jan; 92(1):12-17. PubMed ID: 27673579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of the Y chromosome predicts a high relapse risk in younger adult male patients with t(8;21) acute myeloid leukemia on high-dose cytarabine consolidation therapy: a retrospective multicenter study.
    Zhou W; Chen G; Gong D; Li Y; Huang S; Wang N; Xu Q; Xiong Q; Jing Y; Lv N; Wang L; Li Y; Yu L
    Leuk Lymphoma; 2020 Apr; 61(4):820-830. PubMed ID: 31724463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.